Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen
Aiforia Technologies Plc, Company Release, Managers’ Transactions, March 12, 2026 at 13:00 EET
Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen
Aiforia Technologies Plc has received a notification from Tuomas Tenkanen, Aiforia Technologies Plc's Board Member, of a transaction made with Aiforia Technologies Plc’s financial instrument, according to the Article 19 of EU Market Abuse Regulation. Detailed information about the transaction is given here under.
____________________________________________
Aiforia Technologies Plc - Managers' transactions - Tenkanen
____________________________________________
Person subject to the notification requirement
Name: TJT Technologies Oy
Position: Chief Executive Officer
(X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer
Name: Tuomas Tenkanen
Position: Member of the Board
Issuer: Aiforia Technologies Oy
LEI: 743700TJRVBX7420Y723
Notification type: INITIAL NOTIFICATION
Reference number: 146827/4/8
____________________________________________
Transaction date: 2026-03-10
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000507934
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 507 Unit price: 1.795 EUR
(2): Volume: 2999 Unit price: 1.795 EUR
(3): Volume: 1200 Unit price: 1.795 EUR
(4): Volume: 3000 Unit price: 1.795 EUR
(5): Volume: 6312 Unit price: 1.785 EUR
Aggregated transactions (5):
Volume: 14018 Volume weighted average price: 1.7905 EUR
____________________________________________
Transaction date: 2026-03-10
Venue: POSIT (XPOS)
Instrument type: SHARE
ISIN: FI4000507934
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 9911 Unit price: 1.79 EUR
Aggregated transactions (1):
Volume: 9911 Volume weighted average price: 1.79 EUR
____________________________________________
Transaction date: 2026-03-11
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000507934
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 90 Unit price: 1.8 EUR
(2): Volume: 10 Unit price: 1.795 EUR
(3): Volume: 500 Unit price: 1.795 EUR
(4): Volume: 500 Unit price: 1.795 EUR
(5): Volume: 3400 Unit price: 1.795 EUR
(6): Volume: 5065 Unit price: 1.795 EUR
(7): Volume: 500 Unit price: 1.795 EUR
(8): Volume: 400 Unit price: 1.795 EUR
(9): Volume: 35 Unit price: 1.795 EUR
(10): Volume: 6100 Unit price: 1.795 EUR
(11): Volume: 500 Unit price: 1.795 EUR
(12): Volume: 4500 Unit price: 1.795 EUR
(13): Volume: 500 Unit price: 1.795 EUR
(14): Volume: 500 Unit price: 1.795 EUR
(15): Volume: 2500 Unit price: 1.795 EUR
(16): Volume: 500 Unit price: 1.795 EUR
(17): Volume: 1500 Unit price: 1.795 EUR
(18): Volume: 365 Unit price: 1.795 EUR
(19): Volume: 635 Unit price: 1.795 EUR
(20): Volume: 571 Unit price: 1.795 EUR
(21): Volume: 2330 Unit price: 1.785 EUR
(22): Volume: 270 Unit price: 1.785 EUR
Aggregated transactions (22):
Volume: 31271 Volume weighted average price: 1.79418 EUR
____________________________________________
Transaction date: 2026-03-11
Venue: DNFI
Instrument type: SHARE
ISIN: FI4000507934
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 300 Unit price: 1.79 EUR
Aggregated transactions (1)
Volume: 300 Volume weighted average price: 1.79 EUR
Further inquiries
Antti Ojala, CFO, Aiforia Technologies Plc
tel. +358 40 7202448
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.
Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.
Find out more at www.aiforia.com